Mykofenolatmofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mykofenolatmofetil Accord, is an immunosuppressant (antimetabolite) presented as an oral formulation for oral use. It is used to prevent organ transplant rejection in adult patients.

GNH USA supplies Mykofenolatmofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Mycophenolate Mofetil is an immunosuppressive agent used primarily in transplant medicine to inhibit lymphocyte proliferation.

- Kidney transplant: reduces the risk of acute rejection. - Heart transplant: lowers incidence of acute rejection episodes. - Liver transplant: helps prevent acute graft rejection.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Infections: increased susceptibility to bacterial, viral, or fungal infections.

Serious or Rare Side Effects: - Leukopenia: marked reduction in white blood cell count. - Anemia: decreased red blood cell production. - Severe infections: opportunistic or life‑threatening infections. - Malignancy: heightened risk of certain cancers with long‑term use.

Patients receiving Mycophenolate Mofetil should be monitored closely for hematologic and infectious complications. - Monitor blood counts: regular CBC to detect leukopenia or anemia. - Assess renal function: adjust therapy if creatinine rises. - Evaluate for infections: treat promptly and avoid live vaccines. - Use contraception: advise effective birth control for women of childbearing potential. - Store at room temperature: keep in the original pack, protect from moisture.

Mycophenolate Mofetil may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Live vaccines: risk of uncontrolled infection. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce drug exposure. - Other immunosuppressants (e.g., azathioprine, tacrolimus): additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Antacids (aluminum or magnesium): may decrease absorption. - NSAIDs: increase risk of renal impairment. - ACE inhibitors or ARBs: potential for enhanced nephrotoxicity.